Publication:
Prevalence and associated risk factors of drug-resistant tuberculosis in Thailand: results from the fifth national anti-tuberculosis drug resistance survey

dc.contributor.authorP. Kamolwaten_US
dc.contributor.authorS. Nateniyomen_US
dc.contributor.authorA. Chaipraserten_US
dc.contributor.authorA. Disratthakiten_US
dc.contributor.authorS. Mahasirimongkolen_US
dc.contributor.authorN. Yamadaen_US
dc.contributor.authorS. Smithtikarnen_US
dc.contributor.otherThailand Ministry of Public Healthen_US
dc.contributor.otherFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
dc.contributor.otherThe Research Institute of Tuberculosis, Japan Anti-Tuberculosis Associationen_US
dc.date.accessioned2020-12-28T05:48:36Z
dc.date.available2020-12-28T05:48:36Z
dc.date.issued2020-01-01en_US
dc.description.abstract© 2020 John Wiley & Sons Ltd Objective: To assess the prevalence and risk factors of drug-resistant tuberculosis (TB), the fifth national anti-TB drug resistance survey was conducted in Thailand. Methods: A cross-sectional study was conducted by stratified cluster sampling with probability proportional to size of TB cases from public health facilities in 100 clusters throughout Thailand from August 2017 to August 2018. Susceptibility testing of TB isolates to first- and second-line anti-TB drugs was performed on Löwenstein–Jensen medium using the indirect proportion method. Multiple imputation was done for handling missing data using Stata 16. The proportion of TB cases with drug resistance was determined. The odds ratio was used to evaluate risk factors associated with drug-resistant TB. Results: Among 1501 new TB and 69 previously treated TB cases, 14.0% [95% confidence interval (CI): 12.1–16.1] and 33.4% (95% CI: 23.6–44.8), respectively, had resistance to any anti-TB drug. Multidrug-resistant TB accounted for 0.8% (95% CI: 0.5–1.4) of new TB cases and 13.0% (95% CI: 6.5–24.4) of previously treated TB cases. Drug-resistant TB was associated with prior TB treatment [odds ratio (OR), 2.9; 95% CI: 1.6–5.0], age at 45–54 years (OR, 1.6; 95% CI: 1.0–2.4), male (OR, 1.5; 95% CI: 1.0–2.1) and human immunodeficiency virus (HIV) infection (OR, 1.6; 95% CI: 1.0–2.4). Conclusions: The burden of drug-resistant TB remains high in Thailand. Intensified prevention and control measures should be implemented to reduce the risks of drug-resistant TB in high-risk groups previously treated, especially individuals of late middle age, males and those with coinfection of TB and HIV.en_US
dc.identifier.citationTropical Medicine and International Health. (2020)en_US
dc.identifier.doi10.1111/tmi.13502en_US
dc.identifier.issn13653156en_US
dc.identifier.issn13602276en_US
dc.identifier.other2-s2.0-85096691335en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/60500
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85096691335&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titlePrevalence and associated risk factors of drug-resistant tuberculosis in Thailand: results from the fifth national anti-tuberculosis drug resistance surveyen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85096691335&origin=inwarden_US

Files

Collections